Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Return to growth: Pfizer thanks Hospira and looks to biosimilars

Pfizer has attributed Hospira’s sterile injectables and biosimilar assets to its return to growth, offsetting 17 quarters of declining sales.

Merck says being a CMO that makes tech is good for clients

Germany's Merck has upped bioreactor capacity at its facility in Martillac, France in an investment it says broadens its biologics manufacturing offering.

Biogen haemophilia spin-out to develop gene therapies and long-acting factors

The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.

'Reshaped manufacturing' means continued investment in biologics capacity, AstraZeneca

Plans to reshape its manufacturing network will include increasing biologics capacity beyond its recent acquisitions and expansions, says AstraZeneca.

Samsung on Samsung: Bioepis selects Biologics as a biosimilars CMO

Samsung Biologics has been contracted by its joint venture entity Samsung Bioepis to manufacturer biosimilars from its facility in Korea.

Shire: ‘Baxalta brings us world-class manufacturing network’

Shire will retain Baxalta’s biologics expertise and continue assessing its manufacturing network following the completion of its $32bn acquisition, expected next month.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...